Advanced search
1 file | 69.16 KB Add to list

Relative effects of statin therapy on stroke and cardiovascular events in men and women - Secondary analysis of the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) study

(2008) Stroke. 39. p.2444-2448
Author
Organization
Abstract
Background and Purpose-In SPARCL, treatment with atorvastatin 80 mg daily reduced stroke risk in patients with recent stroke or TIA and no known coronary heart disease by 16% versus placebo over 4.9 years of follow-up. The purpose of this secondary analysis was to determine whether men and women similarly benefited from randomization to statin treatment. Methods-The effect of sex on treatment-related reductions in stroke and other cardiovascular outcomes were analyzed with Cox regression modeling testing for sex by treatment interactions. Results-Women (n = 1908) constituted 40% of the SPARCL study population. At baseline, men (n = 2823) were younger (62.0 +/- 0.21 ersus 63.9 +/- 0.27 years), had lower systolic BPs (138.1 +/- 0.35 versus 139.5 +/- 0.47 mm Hg), higher diastolic BPs (82.2 +/- 0.20 versus 81.0 +/- 0.25 mm Hg), more frequently had a history of smoking (73% versus 38%), and had lower total cholesterol (207.0 +/- 0.54 versus 218.9 +/- 0.67 mg/dL) and LDL-C levels (132 +/- 0.45 versus 134 +/- 0.57 mg/dL) than women. Use of antithrombotics and antihypertensives were similar. After prespecified adjustment for region, entry event, time since event, and age, there were no sex by treatment interactions for the combined risk of nonfatal and fatal stroke (treatment Hazard Ratio, HR = 0.84, 95% CI 0.68, 1.02 in men versus HR = 0.84, 95% CI 0.63, 1.11 in women; treatment x sex interaction P = 0.99), major cardiac events (HR = 0.61, 95% CI 0.42, 0.87 in men versus HR = 0.76, 95% CI 0.48, 1.21 in women; P = 0.45), major cardiovascular events (HR = 0.78, 95% CI 0.65, 0.93 in men versus HR = 0.84, 95% CI 0.65, 1.07 in women; P = 0.63), revascularization procedures (HR = 0.50, 95% CI 0.37, 0.67 in men versus HR = 0.76, 95% CI 0.46, 1.24 in women; P = 0.17), or any CHD event (HR = 0.54, 95% CI 0.41, 0.72 in men versus 0.67 95% CI 0.46, 0.98 in women; P = 0.40). Conclusion-Stroke and other cardiovascular events are similarly reduced with atorvastatin 80 mg/d in men and women with recent stroke or TIA.

Downloads

  • (...).pdf
    • full text
    • |
    • UGent only
    • |
    • PDF
    • |
    • 69.16 KB

Citation

Please use this url to cite or link to this publication:

MLA
Goldstein, L, P Amarenco, M Lamote, et al. “Relative Effects of Statin Therapy on Stroke and Cardiovascular Events in Men and Women - Secondary Analysis of the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Study.” Stroke 39 (2008): 2444–2448. Print.
APA
Goldstein, L., Amarenco, P., Lamote, M., Gilbert, S., Messig, M., Callahan, A., Hennerici, M., et al. (2008). Relative effects of statin therapy on stroke and cardiovascular events in men and women - Secondary analysis of the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) study. Stroke, 39, 2444–2448.
Chicago author-date
Goldstein, L, P Amarenco, M Lamote, S Gilbert, M Messig, A Callahan, M Hennerici, et al. 2008. “Relative Effects of Statin Therapy on Stroke and Cardiovascular Events in Men and Women - Secondary Analysis of the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Study.” Stroke 39: 2444–2448.
Chicago author-date (all authors)
Goldstein, L, P Amarenco, M Lamote, S Gilbert, M Messig, A Callahan, M Hennerici, H Sillesen, K Welch, SPARCL Investigators, and Jan De Bleecker. 2008. “Relative Effects of Statin Therapy on Stroke and Cardiovascular Events in Men and Women - Secondary Analysis of the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Study.” Stroke 39: 2444–2448.
Vancouver
1.
Goldstein L, Amarenco P, Lamote M, Gilbert S, Messig M, Callahan A, et al. Relative effects of statin therapy on stroke and cardiovascular events in men and women - Secondary analysis of the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) study. Stroke. 2008;39:2444–8.
IEEE
[1]
L. Goldstein et al., “Relative effects of statin therapy on stroke and cardiovascular events in men and women - Secondary analysis of the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) study,” Stroke, vol. 39, pp. 2444–2448, 2008.
@article{527808,
  abstract     = {Background and Purpose-In SPARCL, treatment with atorvastatin 80 mg daily reduced stroke risk in patients with recent stroke or TIA and no known coronary heart disease by 16% versus placebo over 4.9 years of follow-up. The purpose of this secondary analysis was to determine whether men and women similarly benefited from randomization to statin treatment.
Methods-The effect of sex on treatment-related reductions in stroke and other cardiovascular outcomes were analyzed with Cox regression modeling testing for sex by treatment interactions.

Results-Women (n = 1908) constituted 40% of the SPARCL study population. At baseline, men (n = 2823) were younger (62.0 +/- 0.21 ersus 63.9 +/- 0.27 years), had lower systolic BPs (138.1 +/- 0.35 versus 139.5 +/- 0.47 mm Hg), higher diastolic BPs (82.2 +/- 0.20 versus 81.0 +/- 0.25 mm Hg), more frequently had a history of smoking (73% versus 38%), and had lower total cholesterol (207.0 +/- 0.54 versus 218.9 +/- 0.67 mg/dL) and LDL-C levels (132 +/- 0.45 versus 134 +/- 0.57 mg/dL) than women. Use of antithrombotics and antihypertensives were similar. After prespecified adjustment for region, entry event, time since event, and age, there were no sex by treatment interactions for the combined risk of nonfatal and fatal stroke (treatment Hazard Ratio, HR = 0.84, 95% CI 0.68, 1.02 in men versus HR = 0.84, 95% CI 0.63, 1.11 in women; treatment x sex interaction P = 0.99), major cardiac events (HR = 0.61, 95% CI 0.42, 0.87 in men versus HR = 0.76, 95% CI 0.48, 1.21 in women; P = 0.45), major cardiovascular events (HR = 0.78, 95% CI 0.65, 0.93 in men versus HR = 0.84, 95% CI 0.65, 1.07 in women; P = 0.63), revascularization procedures (HR = 0.50, 95% CI 0.37, 0.67 in men versus HR = 0.76, 95% CI 0.46, 1.24 in women; P = 0.17), or any CHD event (HR = 0.54, 95% CI 0.41, 0.72 in men versus 0.67 95% CI 0.46, 0.98 in women; P = 0.40).

Conclusion-Stroke and other cardiovascular events are similarly reduced with atorvastatin 80 mg/d in men and women with recent stroke or TIA.},
  author       = {Goldstein, L and Amarenco, P and Lamote, M and Gilbert, S and Messig, M and Callahan, A and Hennerici, M and Sillesen, H and Welch, K and Investigators, SPARCL and De Bleecker, Jan},
  issn         = {0039-2499},
  journal      = {Stroke},
  language     = {eng},
  pages        = {2444--2448},
  title        = {Relative effects of statin therapy on stroke and cardiovascular events in men and women - Secondary analysis of the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) study},
  url          = {http://dx.doi.org/10.1161/STROKEAHA.107.513747},
  volume       = {39},
  year         = {2008},
}

Altmetric
View in Altmetric
Web of Science
Times cited: